Kubuschok, Boris http://orcid.org/0000-0001-5000-2328
Otremba, Burkhard
Welslau, Manfred
Topaly, Julian http://orcid.org/0000-0003-2123-4829
Wolff, Thomas
Lenz, Georg
Grau, Michael
Bittencourt da Silva, Larissa
Brückmann, Ines
Foierl, Tobias
Funding for this research was provided by:
Universitätsklinikum Augsburg
Article History
Received: 29 February 2024
Accepted: 10 June 2024
First Online: 20 June 2024
Declarations
:
: This study was conducted in accordance with applicable Good Clinical Practice guidelines, and with the ethical principles laid down in the Declaration of Helsinki. All patients provided written informed consent prior to entry into the study. Ethics approval for the study was obtained from the following ethics committees: Landesärztekammer Baden-Württemberg Ethik-Kommission, Sächsische Landesärztekammer – Ethik-Kommission, Ärztekammer Hamburg – Ethik-Kommission, Ethik-Kommission der Ärztekammer Nordrhein, Carl von Ossietzky Universität Oldenburg, Medizinische Ethik-Kommission, Ethik-Kommission der Ärztekammer Westfalen-Lippe und der Westfälischen Wilhelms-Universität Münster, Ethik-Kommission bei der Ärztekammer Niedersachsen, Ethik-Kommission des Landes Sachsen-Anhalt, Geschäftsstelle Dessau, Ethik-Kommission der Universität zu Lübeck, and Ethik-Kommission bei der Landesärztekammer Rheinland-Pfalz.
: B Kubuschok: BK has received grants/research support from Roche, MorphoSys, Merck, Sharp & Dohme and Hexal. BK has received honoraria from Roche. B Otremba: BO has received honoraria for presentations and for attending advisory boards for Sandoz. M Welslau: MW has carried out consulting or expert work for AMGEN, Bristol-Myers Squibb, Celgene, GILEAD, Hexal, Janssen, Lilly, Medac, Novartis, Roche, Sanofi, Astra Zeneca. MW has received honoraria from Amgen, Astellas, AstraZeneca, Celgene, GILEAD, Hexal, Janssen, Lilly, NOVARTIS, Roche, SANOFI. J Topaly: Invited speaker for AbbVie, AstraZeneca, Oncopeptides, Janssen, Eli Lilly, Novartis, Roche, and Sanofi. Travel grants from AbbVie, BeiGene, and Eli Lilly. Member of advisory boards for Janssen and Roche. T Wolff: Nothing to disclose. G Lenz: GL has received research support from Roche, Gilead, Janssen, Bayer, Celgene, Novartis, AstraZeneca, and MorphoSys. GL has been a member of an advisory board for Roche, Gilead, Janssen, Bayer, Celgene, Novartis, AstraZeneca, Takeda, Bristol Myers Squibb (BMS), NanoString, AbbVie, Incyte, MorphoSys, Genmab, Karyopharm, Constellation, ADC, Miltenyi, PentixaPharm, Sobi, and Hexal/Sandoz. GL has been an invited speaker for Roche, Janssen, Bayer, Celgene, Takeda, BMS, AbbVie, Incyte, MorphoSys, Sobi, and Hexal/Sandoz, and has consulted for Immagene, Genase, and Eli Lilly. M Grau: Nothing to disclose. L Bittencourt da Silva: Nothing to disclose. I Brückmann: Nothing to disclose. T Foierl: Nothing to disclose.